MTD
Mettler-Toledo International Inc.
NYSE · Healthcare · Medical - Diagnostics & Research · US
$1,354.60
−0.12%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.1B | 4.0B | 3.9B | 3.8B | 3.9B |
| Cost of Revenue | 1.7B | 1.7B | 1.6B | 1.6B | 1.7B |
| Gross Profit | 2.5B | 2.3B | 2.3B | 2.2B | 2.2B |
| Operating Expenses | |||||
| R&D Expense | 208.0M | 199.4M | 189.4M | 185.3M | 177.1M |
| SG&A Expense | 1.0B | 998.3M | 936.3M | 904.1M | 938.5M |
| General & Admin Expense | 263.3M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 27.2M | — | — | — | — |
| Total Operating Expenses | 1.3B | 1.2B | 1.1B | 1.1B | 1.1B |
| Cost and Expenses | 2.9B | 2.9B | 2.7B | 2.7B | 2.8B |
| Operating Income (EBIT) | 1.2B | 1.1B | 1.1B | 1.1B | 1.1B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 69.3M | 68.5M | 74.6M | 77.4M | 55.4M |
| Net Interest Income | (69.3M) | (68.5M) | (74.6M) | (77.4M) | (55.4M) |
| Other Non-Op Income/Expense | (88.7M) | (69.6M) | (89.8M) | (106.0M) | (55.6M) |
| Non-Operating Income (excl Interest) | 21.3M | 9.4M | 26.6M | 17.7M | (4.2M) |
| EBT (Pre-Tax Income) | 1.1B | 1.0B | 1.0B | 973.7M | 1.1B |
| Income Tax Expense | 191.8M | 179.7M | 174.1M | 184.9M | 198.1M |
| Bottom Line | |||||
| Net Income | 905.6M | 869.2M | 863.1M | 788.8M | 872.5M |
| Earnings from Cont. Ops | 905.6M | 869.2M | 863.1M | 788.8M | 872.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 905.6M | 869.2M | 863.1M | 788.8M | 872.5M |
| Per Share | |||||
| Basic EPS | $44.51 | $42.17 | $40.67 | $36.10 | $38.79 |
| Diluted EPS | $44.49 | $42.17 | $40.67 | $35.90 | $38.41 |
| Revenue Per Share | $205.45 | $195.36 | $182.47 | $173.39 | $174.27 |
| Shares | |||||
| Basic Shares Outstanding | 20.1M | 20.6M | 21.2M | 21.8M | 22.5M |
| Diluted Shares Outstanding | 20.2M | 20.6M | 21.3M | 22.0M | 22.7M |
| Profitability Metrics | |||||
| EBITDA | 1.3B | 1.2B | 1.2B | 1.2B | 1.2B |
| D&A | 131.0M | 125.6M | 123.2M | 121.2M | 113.0M |
| EBIT | 1.2B | 1.1B | 1.1B | 1.1B | 1.1B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026